Abstract
Patients with previously untreated squamous cell lung carcinomas were evaluated to see if combining the expression of molecular and cellular factors with the most important clinical prognostic factors could improve the diagnostic ability to predict prognosis. For this reason, immunohistochemistry was used to examine the squamous cell lung carcinomas from 121 patients for their expression of ERBB-1, vascular endothelial growth factor (VEGF), cyclin A, FOS, JUN and MYC. Median survival was shorter for patients with ERBB-1-, VEGF-, cyclin A-, FOS-, or JUN-positive tumours. For those patients with positive lymph node involvement, the survival times were also shorter in the VEGF-positive, cyclin A-positive and FOS-positive groups. Multivariate analysis independently demonstrated a significant prognostic value for lymph node involvement, VEGF and FOS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Volm, M., Rittgen, W. & Drings, P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77, 663–669 (1998). https://doi.org/10.1038/bjc.1998.106
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.106
This article is cited by
-
Multiclass cancer classification in fresh frozen and formalin-fixed paraffin-embedded tissue by DigiWest multiplex protein analysis
Laboratory Investigation (2020)
-
Effect of chemotherapy on quality of life in patients with non-small cell lung cancer
Supportive Care in Cancer (2014)
-
MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis
Tumor Biology (2014)
-
Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer
Tumor Biology (2014)
-
Translationale Forschung und Diagnostik beim Lungenkarzinom
Der Pathologe (2012)